BSE filing, NSE: JAYBARMARU. Summary written from the filing by ALFA Finder's alert engine.
Jay Bharat Maruti Ltd: key numbers
- Share price
- ₹114.91
- Market cap
- ₹1,244 Cr
- Revenue (annual)
- ₹2,551 Cr
- Net profit (annual)
- ₹139.7 Cr
- P/E (TTM)
- 9.0×Sector 30.5×
- Promoter holding
- 59.35%+0.00% QoQ
- FII holding
- 1.16%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Jay Bharat Maruti Ltd
All →Jay Bharat Maruti Board Meeting Date
Jay Bharat Maruti has scheduled a Board meeting on Nov 2, 2026 to consider Q2/H1 FY27 unaudited results and other matters. Trading window remains closed until Nov 4, 2026.
Jay Bharat Maruti Price Movement Clarification
Jay Bharat Maruti responded to NSE surveillance query stating no material information explains the volume spike. The company confirmed volumes are purely market-driven with no undisclosed UPSI.
Jay Bharat Maruti Other Announcement
Jay Bharat Maruti reported zero requests received for transfer and demat of physical shares under the SEBI special window for Sept–Oct 2026. This is a routine nil compliance return with no business or financial impact.
Jay Bharat Maruti Management Change
Jay Bharat Maruti Limited announced the resignation of Ms. Shubha Singh as the Company Secretary and Compliance Officer, effective September 19, 2026.
Jay Bharat Maruti Other Announcement
Jay Bharat Maruti Limited reported nil requests for physical share transfer and demat for the period August 05 to September 04, 2026, as per regulatory compliance requirements.
Jay Bharat Maruti Annual General Meeting
Jay Bharat Maruti Ltd held its 39th Annual General Meeting on August 26, 2026. Shareholders discussed company performance and voted on several ordinary and special business resolutions.
Other regulatory approval announcements
All →Nesco Regulatory Approval
Nesco Limited received a Commencement Certificate from BMC for Tower-2 and Hall-1 at Nesco Center, Goregaon. The company can now proceed with construction and development of the proposed projects, valid until 29 October 2027.
Grasim Industries Regulatory Approval
CCI approved subsidiary ABReN's acquisition of 100% of Solenergi Power from Shell Overseas. The approval clears a regulatory condition for the deal announced on 13 July 2026.
Vedavaag Systems Regulatory Approval
Vedavaag's WOS received IRDAI Certificate of Registration to act as Direct Life & General Insurance Broker. The group enters regulated insurance broking activity.
Hikal Regulatory Approval
Hikal's Bengaluru API facility received a Swissmedic GMP Certificate of Compliance. The certification supports wider access to European and other regulated markets.
Sun Pharmaceutical Industries Regulatory Approval
Sun Pharma gained US FDA approval for ILUMYA in adults with active psoriatic arthritis. The approval extends the drug's psoriasis use, with no financial value stated.
RNFI Services Regulatory Approval
RNFI received RBI no-objection to acquire control of Smart Payment Solutions Private Limited. Remaining tranches may proceed, but no transaction value is disclosed.